CE

# *Candida albicans* IgA ELISA Kit (GD19)
Semi-quantitative assay for *Candida albicans* IgA

# *Candida albicans* IgM ELISA Kit (GD20)
Semi-quantitative assay for *Candida albicans* IgM

# *Candida albicans* IgG ELISA Kit (GD22)
Quantitative assay for *Candida albicans* IgG

(96 tests)

For *in vitro* diagnostic use

100108

**1. Intended use**

The *Candida albicans* IgA, IgM and IgG kits are rapid ELISA methods for the detection of IgA, IgM or IgG antibodies to *Candida albicans*. They are intended for the diagnosis of *Candida albicans* infection. The components of the kits are for *in vitro* diagnostic use only.

**2. Explanation of the Test**

A number of fungal pathogens can spread systemically from the intestinal lumen to the visceral organs. Although hundreds of Candida species are known, *C. albicans* and *C. tropicalis* cause over 80% of Candida infections in man. Candida probably enters the newborn in the first days of life and is a normal inhabitant of the gut. Systemic candidiasis is a fungal infection of the deep organs resulting from the overgrowth and spread of Candida. It is a significant cause of death in immuno-compromised patients or those undergoing prolonged antibiotic therapy. Candida infection is not routinely tested for in blood donors and may also be transmitted via blood transfusions. Elevated Candida IgG levels are also frequently encountered in elderly patients (>60 years).

Recent infection with systemic candidiasis is characterised by elevated IgM and IgG titres. Candida IgA antibodies are associated with mucosal membrane infections. We recommend that patients with suspected candidiasis are screened for all three antibody classes.

**3. Principle of the test**

Diluted serum samples are incubated with *C. albicans* antigens immobilised on microtitre wells. After washing away unbound serum components, rabbit anti-human IgA, IgM or IgG conjugated to horseradish peroxidase is added to the wells, and this binds to surface-bound antibodies in the second incubation. Unbound conjugate is removed by washing, and a solution containing 3,3',5,5'-tetramethylbenzidine (TMB) and enzyme substrate is added to trace specific antibody binding. Addition of stop solution terminates the reaction and provides the appropriate pH for colour development. The optical densities of the standards, positive control and samples are measured using a microplate reader at 450nm. Optical density is directly proportional to antibody activity in the sample.

**4. Materials included in the kit**

- **Microplate:** 96 wells in 12 X 8 break-apart strips, pre-coated with *C.albicans* antigens, with holder in a foil bag with desiccant
- **Reagent 1**: **Sample Diluent** 10 mM Tris-buffered saline, pH 7.2 with antimicrobial agent, 100ml, (blue), ready to use
- **Reagent 2: Wash Buffer** 100mM Tris-buffered saline with detergent, pH 7.2, 100 ml, **concentrate** (x10)
- **Reagent 3: Conjugate** rabbit anti-human IgA (yellow) or IgM (green) or IgG (red) conjugated to horseradish peroxidase in protein stabilising solution and antimicrobial agent, 12 ml, ready to use
- **Reagent 4: TMB Substrate** aqueous solution of TMB and hydrogen peroxide, 12 ml, ready to use
- **Reagent 5: Stop Solution** 0.25M sulphuric acid, 12 ml, ready to use
- **Standards:** 1ml of 10mM Tris-buffered saline containing either human serum IgA antibodies to *C.albicans*, (0, 50 U/ml), or IgM antibodies (0, 10 U/ml), or IgG antibodies (0, 12.5, 25, 50, & 100 U/ml), ready to use
- **Positive control:** 1ml of 10mM Tris-buffered saline containing either human serum IgA, IgM or IgG antibodies to *C.albicans*, ready to use
- **Instructions for use**

**5. Other equipment required**

1. Test tubes for dilution • graduated cylinder for preparing wash buffer • precision pipettes and disposable tips to deliver 5µl, 100µl, 1ml • EIA microplate washer or multi-channel pipette or wash bottle • distilled or de-ionised water • absorbent paper • EIA microplate reader with 450nm and optional 620nm reference filter. Alternatively, a suitable automated system may be used.
2. Instrumentation, whether manual or automated, should meet the following criteria: pipettes with better than 3% imprecision with no carry over between pipetting steps; microplate washers should remove 99% of fluid; automated machines should minimise time between washing and adding the next reagent.

**6. Precautions**

**6.1 Safety Precautions**

1. All reagents in this kit are for *in vitro* diagnostic use only.
2. Only experienced laboratory personnel should use this test. The test protocol must be followed strictly.
3. All human source material used in the preparation of standards and the positive control for this product have been tested and found negative for antibodies to HIV, HbsAg and HCV. No test method, however, can offer complete assurance that infectious agents are absent. Therefore, all reagents containing human material should be handled as if potentially infectious. Operators should wear gloves and protective clothing when handling any patient sera or serum based products.
4. Reagents of this kit contain antimicrobial agents and the Substrate solution contains 3,3',5,5'-tetramethylbenzidine. Avoid contact with the skin and eyes. Rinse immediately with plenty of water if any contact occurs.
5. The Stop Solution contains 0.25M sulphuric acid. Avoid contact with skin and eyes. Rinse immediately with plenty of water if contact occurs.
6. Any liquid that has been brought into contact with potentially infectious material has to be discarded in a container with a disinfectant. Disposal must be performed in accordance with local legislation.

**6.2 Technical Precautions**

1. Strips and solutions should not be used if the foil bag is damaged or liquids have leaked.
2. Allow all reagents and the microplate to reach room temperature before use. Ensure that the microplate foil bag containing any unused strips is well sealed and contains the desiccant to avoid moisture. Store at 2 – 8°C after use.
3. When automating, consider excess volumes required for setting up the instrument and dead volume of robot pipette
4. Include the positive control in every test run to monitor for reagent stability and correct assay performance.
5. Strictly observe the indicated incubation times and temperature.
6. Ensure that no cross-contamination occurs between wells. Keep all pipettes and other equipment used for enzyme conjugate completely separate from the substrate reagent.
7. When pipetting Conjugate or Substrate, aliquots for the required numbers of wells should be taken to avoid multiple entry of pipette tips into the reagent bottles. Never pour unused reagents back into the original bottles.
8. Do not allow microwells to dry between incubation steps.
9. Strictly follow the described wash procedure. Insufficient washing may cause high background signal.
10. Avoid direct sunlight and exposure to heat sources during all incubation steps.
11. Replace colour-coded caps on their correct vials to avoid cross-contamination
12. It is important to dispense all samples and the positive control into the wells without delay. Therefore ensure that all samples are ready to dispense.

**7. Shelf life and storage conditions**

On arrival, store the kit at 2 – 8°C. Once opened the kit is stable for 3 months (or until its expiry date if less than 3 months). Do not use kits beyond their expiry date. Do not freeze any kit component. The diluted Wash Buffer has a shelf life of 3 months if stored in a closed bottle at 2 – 8°C.

**8. Specimen collection and storage**

Serum or plasma samples may be used and should be stored at -20°C for long-term storage. Frozen samples must be mixed well after thawing and prior to testing. Repeated freezing and thawing can affect results.
Addition of preservatives to the serum sample may adversely affect the results. Microbially contaminated, heat-treated or specimens containing particulate matter should not be used. Grossly haemolysed, icteric or lipaemic specimens should be avoided.

**9. Preparation of reagents**

Dilute the Wash Buffer (**Reagent 2)** 1: 9 in distilled water to make sufficient buffer for the assay run e.g. add 50ml wash buffer concentrate to 450ml water.

**10. Assay Procedure**

1. Dilute patient samples 1:200 in sample diluent (e.g. 5μl serum plus 1ml diluent).

2. Allow the diluted samples to stand for **30** minutes. The sample diluent contains an immunoadsorbent that removes non-candida antibodies

3. Assemble the number of strips required for the assay.

4. Dispense 100 μl of each standard, and positive control and the diluted patient samples into appropriate wells.

5. Incubate for **30** minutes at room temperature.

6. After 30 minutes, decant or aspirate the well contents and wash the wells 3 times using automated washing or the manual wash procedure (see below). Careful washing is the key to good results. **Do not allow the wells to dry out.**

   Manual Wash Procedure:
   Empty the wells by inversion. Using a multi-channel pipette or wash bottle, fill the wells with wash buffer. Empty by inversion and blot the wells on absorbent paper. Repeat this wash process 2 more times.

7. Dispense 100μl of Conjugate (**Reagent 3)** into each well. Incubate the wells for **30** minutes at room temperature.

8. After 30 minutes, discard the well contents and carefully wash the wells 4 times with wash buffer. Ensure that the wells are empty but do not allow to dry out.

9. Using a repeating dispenser, rapidly dispense 100μl of TMB Substrate (**Reagent 4)** into each well. Incubate the plate for **10** minutes.

10. Add 100μl of Stop Solution (**Reagent 5)** to each well. To allow equal reaction times, the Stop Solution should be added to the wells in the same order as the TMB Substrate.

11. Read the optical density (OD) of each well at 450nm in a microplate reader within 10 minutes. A 620nm filter may be used as a reference wavelength for dual wavelength measurements.

**11. Quality control**

Quality control data is supplied on the lot-specific QC certificate included in the kit.

The positive control is intended to monitor for substantial reagent failure.

Any well positive by spectrophotometer but without visible colour should be cleaned on the underside and re-read. If OD-values below zero are observed, the wavelengths used should be verified, the reader re-blanked to air and the measurements repeated.

**12. Interpretation of Results**

IgA
Plot the optical density of the 0 and 50 U/ml standard. Read the unknowns off this line. In our laboratory, we have established normal values to be less than 10 U/ml. Patients with IgA values above 10 U/ml are likely to have had a recent or current Candida infection.

IgM
Plot the optical density of the 0 and 10 U/ml standard. Read the unknowns off this line. Samples with values above 10 U/ml are positive for *C. albicans* IgM. (See Limitations of the Procedure)

IgG
Plot the optical density of each standard against its concentration and draw the best-fit curve through the points. Read the unknowns off this curve. We have established normal values to be less than 30 U/ml for Candida IgG. The presence of Candida IgG antibodies is an indicator of host response to infection by Candida (see Limitations of the Procedure).

**13. Limitations of the Procedure**

1. A positive test does not necessarily indicate infection since antibodies to *Candida* species can be detected in uninfected individuals because of their exposure to commensal yeasts
2. Assays are unable to differentiate antibodies formed during mucosal colonisation from those produced during deep infection. In consequence antibodies are found in many hospitalised patients who have no obvious *Candida* infection.
3. A negative antibody test similarly does not necessarily rule out the possibility of deep-seated candidiasis in immuno-compromised patients who are incapable of mounting an adequate antibody response.
4. Antibody tests are of diagnostic value providing the results are interpreted with caution and in the light of other clinical and laboratory findings. They are most useful when a series of tests is performed at regular intervals over time. A high or rapidly rising antibody titre suggests infection and conversely a reduction in titre indicates recovery.

**14. Performance Characteristics**

The performance of the Candida IgG ELISA was evaluated using samples supplied by UK NEQAS. Results obtained by the ELISA are compared with the designated responses (DR) obtained for samples included in the scheme.

| | DR + | DR- |
|---|---|---|
| Candida IgGELISA + | 5 | 1 |
| Candida IgG ELISA - | 1 | 12 |

**15. Reproducibility**

Candida IgA ELISA
Within assay coefficient of variation: 4 - 8%
Between assay coefficient of variation: 5 - 12%

Candida IgM ELISA
Within assay coefficient of variation: 4 - 6%
Between assay coefficient of variation: < 12%%

Candida IgG ELISA
Within assay coefficient of variation: 4 - 7%
Between assay coefficient of variation: < 12%

**Method Summary**

- Dilute sera 1:200 with sample diluent **(Reagent 1)**
- Incubate samples in diluent for **30 minutes**
- Dispense standards (as required), the positive control and the diluted samples into the microplate wells
- Incubate for **30** minutes at room temperature.
- *Wash the wells three times*
- Dispense 100μl of conjugate **(Reagent 3)** into each well
- Incubate at room temperature for **30** minutes
- *Wash the wells four times*
- Add 100μl of TMB substrate **(Reagent 4)** to each well
- Incubate at room temperature for **10** minutes
- Add 100μl stop solution **(Reagent 5)** to each well
- Read the optical density at 450nm (single wavelength) or 450/620nm (dual wavelength).

**Further reading**


Faux, J A et al (1992) Comparison of specific IgG antibody levels to the cell wall mannan of *Candida albicans* in normal individuals and in patients with primary antibody deficiency. *J Immunol Methods* 153, 167 - 172
McHugh T M et al (1989) Development of a microsphere based fluorescent immunoassay and it comparison to an enzyme immunoassay for the detection of antibodies to three preparations of *Candida albicans J Immunol Methods* 116, 213-219
Burnie J P et al (1985) Outbreak of systemic *Candida albicans* in intensive care unit caused by cross infection. *Brit Med J* 290, 746-748
Crook, W G (1983) The yeast connection: A medical breakthrough. Professional Books, PO Box 3494, Jackson, TN 38301
Robinet, RW Asthma due to C. *albicans Univ Michigan, Med Centre Bulletin* 34, 12 - 15
Ray, TL (1980) Fungal infections in the immuno-compromised host. *Med Clin N America* 64, 955 - 968.
Wojdani, A M et al (1986) Measurement of humoral and cellular immunity for the diagnosis of Candidiasis. *Clin Ecol* 4, 210



Genesis Diagnostics Ltd, Eden Research Park, Henry Crabb Road, Littleport, Cambridgeshire CB6 1SE, UK.
Tel: +44 (0)1353 862220 Fax: +44 (0)1353 863330 email: genesis@elisa.co.uk web: www.elisa.co.uk
Genesis is a subsidiary of Omega Diagnostics Group plc